Evommune’s EVO301 met the goals of a placebo-controlled Phase 2a study in atopic dermatitis. The biologic drug neutralizes a signaling protein involved in multiple inflammatory pathways, which could differentiate it from the blockbuster Sanofi and Regeneron Pharmaceuticals immunology drug Dupixent.
The post Evommune Starts Making Case to Challenge Dominance of Sanofi’s Dupixent in Atopic Dermatitis appeared first on MedCity News.
